High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: A confirmatory prospective study

Cancer

Volumn 110, Issue 10, 2007, Pages 2178-2185

  Colomer, Ramon ^a   Llombart Cussac, Antonio ^b   Lloveras, Belen ^c   Ramos, Manuel ^d   Mayordomo, Jose I ^e   Fernández, Roberto ^f   Tusquets, Ignasi ^g   Gil, Miguel ^c   Barnadas, Agusti ^h   Constenla, Manuel ⁱ   Gilabert, Montserrat ^j   Alba, Emilio ^k  

^a MD ANDERSON CANCER CENTER   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d Regional Cancer Center of Galicia   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL DE CABUEÑES   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h University Hospital of St Pau (Cardiology)   (Spain)

ⁱ HOSPITAL MONTECELO   (Spain)

^j Novartis Pharma   (Spain)

^k Virgen de la Victoria University Hospital   (Spain)

more..

Author keywords

Aromatase inhibitor; Breast cancer; Efficacy; erbB 2; Estrogen receptor; Extracellular domain; HER 2; Letrozole; Response; Time to progression

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; NEOPLASM METASTASIS; NITRILES; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 36048939321     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23043     Document Type: Article

References (30)

1. Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989;6:148-155.
2. Lupu R, Lippman ME, William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat. 1993;27(1-2):83-93.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2 proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
4. Mori S, Mori Y, Mukaiyama T, et al. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res. 1990;81:489-494.
5. Carney WP, Hamer PJ, Petit D, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol. 1991;6:53-72.
6. Langton BC, Crenshaw MC, Chao LA, et al. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res. 1991;51:2593-2598.
7. Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003;49:1579-1598.
8. Colomer R, Montera S, Lluch A, et al. Circulating HER-2/neu extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000;6:2356-2362.
9. Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER-2/neu extracellular domain. Ann Oncol. 2004;15:201-206.
10. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. [letter]. J Clin Oncol. 2002;20:4605; author reply, 4606.
11. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15:2518-2525.
12. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 79(7-8):1220-1226, 1999.
13. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101-2109.
14. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003;21:1967-1972.
15. Colomer R, Llombart A, Ramos M, et al. Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study, [abstract]. Breast Cancer Res Treat. 2001;69:242.
16. Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004;5:105-116.
17. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452-8458.
18. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24:3019-3025.
19. Muller V, Witzel I, Luck HJ, et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004;86:9-18.
20. Lonn U, Lonn S, Ingelman-Sundberg H, et al. C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Int J Cancer. 1996;69:273-277.
21. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005;16:234-239.
22. Pallud C, Guinebretiere JM, Guepratte S, et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res. 2005;25(2B):1433-1440.
23. Kong SY, Nam BH, Lee KS, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem. 2006;52:1510-1515.
24. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21:46-53.
25. Falo C, Moreno A, Lloveras B, Figueras A, Varela M, Escobedo A. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. Am J Clin Oncol. 2003;26:465-470.
26. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-1624.
27. Luftner D, Cheli C, Mickelson K, Sampson E, Possinger K. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers. 2004;19:175-182.
28. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512-7517.
29. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11:541-552.
30. Kaufman B, Mackey J, Clemens M, et al. Trastuzumab plus anastrozole prolongs progression-free survival in post-menopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). [abstract]. Ann Oncol. 2006;17(suppl 9):LBA2.